Centre d'Estudis Epidemiològics sobre les ITS i Sida de Catalunya

You are here

2012 | CEEISCAT

Publicacions 2012

 

Romero A, González V, Esteve A, Martró E, Matas L, Tural C, Pumarola T, Casanova A, Ferrer E, Caballero E, Ribera E, Margall N,Domingo P, Farré J, Puig T, Sauca MG, Barrufet P, Amengual MJ, Navarro G, Navarro M, Vilaró J, Ortín X, Ortí A, Pujol F, Prat JM,Massabeu A, Simó JM, Villaverde CA, Benítez MA, Garcia I, Díaz O, Becerra J, Ros R, Sala R, Rodrigo I, Miró JM, Casabona J; the AERI Study group. Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08). Eur J Public Health. 2012 Dec;22(6):802-8.

 

Antiretroviral Cohort Collaboration. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol. 2012 Dec; 41(6):1807-20. doi: 10.1093/ije/dys164

 

Agustí C, Mascort J, Carrillo R, Casabona J. Detección precoz de la infección por el virus de la inmunodeficiencia humana en el contexto de Atención Primaria [Editorial]. Aten Primaria. 2012 Dec;44(12):689-90.

 

Marcus U, Hickson F, Weatherburn P, Schmidt AJ; The EMIS Network. Prevalence of HIV among MSM in Europe: comparison of self-reported diagnoses from a large scale internet survey and existing national estimates. BMC Public Health. 2012 Nov 14;12(1):978. doi:10.1186/1471-2458-12-978.

 

Stuardo V, Agustí C, Godinez JM, Montoliu A, Torné A, Tarrats A, Alcalde C, Martín D, Fernández-Montoli E, Vanrell C, Solé J, Canet Y, Marqueta JM, Mohamed J, Cuenca I, Lonca M, Sirera G, Ferrer E, Domingo P, Lloveras B, Miro JM, De Sanjosé S, Casabona J. Human Papillomavirus Infection in HIV-1 Infected Women in Catalonia (Spain): Implications for Prevention of Cervical Cancer. PLoS One 2012;7(10):e47755. doi: 10.1371/journal.pone.0047755.

 

Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012 Aug;67(8):1858-60. doi: 10.1093/jac/dks162.

 

The HIV-CAUSAL Collaboration. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS. 2012 Aug 24;26(13):1691-705. doi: 10.1097/QAD.0b013e328354f497.

 

Vives N, Carnicer-Pont D, García de Olalla P, Camps N, Esteve A, Casabona J; the HIV and STI Surveillance Group. Factors associated with late diagnosis of HIV infection in Catalonia, Spain. Int J STD. AIDS. 2012 Jul;23(7):475-80. doi: 10.1258/ijsa.2011.011280.

 

Sabidó M, Gregg LP, Vallès X, Nikiforov M, Monzón JE, Pedroza MI, Vermund SH, Casabona J. Notification for sexually transmitted infections and HIV among sex workers in Guatemala: acceptability, barriers, and preferences. Sex Transm Dis. 2012 Jul;39(7):504-8. doi: 10.1097/OLQ.0b013e31824f8b1b.

 

Agustí C, Sabidó M, Guzmán K, Pedroza MI, Casabona J. Proyecto de atención integral a víctimas de violencia sexual en el departamento de Escuintla, Guatemala. Gac Sanit. 2012 Jul;26(4):376–8. doi: 10.1016/j.gaceta.2011.12.014.

 

Corbeto EL, Carnicer-Pont D, Lugo R, Gonzalez V, Bascuñana E, Lleopart N, Barbero L, Humet V, Casabona J, Chlamydia Study Group In Catalonia Prisons. Sexual behaviour of inmates with Chlamydia trachomatis infection in the prisons of Catalonia, Spain. Sex Health. 2012 May;9(2):187-9. doi: dx.doi.org/10.1071/SH11038.

 

The HIV-CAUSAL Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203.

 

Carnicer-Pont D, Smithson A, Fina-Homar E, Bastida MT; the Gonococcus antimicrobial resistance surveillance working group. First cases of Neisseria gonorrhoeae resistant to ceftriaxone in Catalonia, Spain, May 2011. Enferm Infecc Microbiol Clin. 2012 Apr;30(4):218-9. doi: 10.1016/j.eimc.2011.11.010.

 

The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord; Lewden Ch, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d’Arminio, Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne1 G. All-cause mortality in treated HIV-infected adults with CD4 ≥500 /mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012 Apr;41(2):433-445. doi: 10.1093/ije/dyr164.

 

Díez M, Oliva J,  Sánchez F,  Vives N,  Cevallosd C, Izquierdo A;  Grupo SINIVIH. Incidencia de nuevos diagnósticos de VIH en España, 2004-2009. Gac Sanit. 2012 Mar-Apr;26(2):107-15. doi: 10.1016/j.gaceta.2011.07.023.

 

Fernández-Dávila P,  Lupiáñez-Villanueva F, Zaragoza Lorca K. Actitudes hacia los programas de prevención on-line del VIH y las ITS, y perfil de los usuarios de Internet en los hombres que tienen sexo con hombres. Gac Sanit. 2012 Mar-Apr;26(2):123-30. doi: 10.1016/j.gaceta.2011.06.011.

 

The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug experienced people with HIV in Europe. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9. doi: 10.1097/QAI.0b013e31823fe66b.

 

The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. CD4 cell count and the risk of AIDS or death in HIV infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012 Mar;9(3):e1001194. doi: 10.1371/journal.pmed.1001194.

 

The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis. 2012 Feb;12(2):119-27. doi: 10.1016/S1473-3099(11)70248-1.

 

Murray M, Hogg RS, Lima VD, May MT, Moore DM, Abgrall S, Bruyand M, D’Arminio Monforte A, Tural C, Gill MJ, Harris RJ, Reiss P, Justice AC, Kirk O, Saag M, Smith CJ, Weber R, Rockstroh J, Khaykin P, Sterne JAC; for the Antiretroviral Therapy Cohort Collaboration (ART-CC). The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.  HIV Med. 2012 Feb;13(2):89-97. doi: 10.1111/j.1468-1293.2011.00940.x.

 

Folch C, Casabona J, Brugal MT, Majó X, Meroño M, Espelt A, González V; Grupo REDAN. Perfil de los usuarios de drogas por vía parenteral que mantienen conductas de riesgo relacionadas con la inyección en Cataluña. Gac Sanit. 2012 Jan-Feb;26(1):37–44. doi: 10.1016/j.gaceta.2011.07.022.

 

Buzon MJ, Erkizia I, Pou C, Minuesa G, Puertas MC, Esteve A, Castello A, Santos JR, Prado JG, Izquierdo-Useros N, Pattery T, Van Houtte M, Carrasco L, Clotet B, Ruiz L, Martinez-Picado J. A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors. J Antimicrob Chemother. 2012 Jan; 67(1):32–8. doi: 10.1093/jac/dkr433.